Identifying and Delineating the Type 2 Diabetes Population in the Netherlands Using an All-payer Claims Database: Characteristics, Healthcare Utilisation and Expenditures

Overview

Journal BMJ Open

Specialty General Medicine

Date 2021 Dec 8

PMID 34876422

Citations 4

Authors

Rose J Geurten

Arianne M J Elissen

Henk J G Bilo

Jeroen N Struijs

Chantal van Tilburg

Dirk Ruwaard

Affiliations

Soon will be listed here.

Abstract

Objectives: We aimed to identify and delineate the Dutch type 2 diabetes population and the distribution of healthcare utilisation and expenditures across the health system from 2016 to 2018 using an all-payer claims database.

Design: Retrospective observational cohort study based on an all-payer claims database of the Dutch population.

Setting: The Netherlands.

Participants: The whole Dutch type 2 diabetes population (n=900 522 in 2018), determined based on bundled payment codes for integrated diabetes care and medication use indicating type 2 diabetes.

Outcome Measures: Annual prevalence of type 2 diabetes, comorbidities and characteristics of the type 2 diabetes population, as well as the distribution of healthcare utilisation and expenditures were analysed descriptively.

Results: In 2018, 900 522 people (6.5% of adults) were identified as having type 2 diabetes. The most common comorbidity in the population was heart disease (12.1%). Additionally, 16.2% and 5.6% of patients received specialised care for microvascular and macrovascular diabetes-related complications, respectively. Most patients with type 2 diabetes received pharmaceutical care (99.1%), medical specialist care (97.0%) and general practitioner consultations (90.5%). In total, €8173 million, 9.4% of total healthcare expenditures, was reimbursed for the type 2 diabetes population. Medical specialist care accounted for the largest share of spending (38.1%), followed by district nursing (12.4%), and pharmaceutical care (11.5%).

Conclusions: All-payer claims databases can be used to delineate healthcare use: this insight can inform health policy and practice and, thereby, support better decisions to promote long-term sustainability of healthcare systems. The healthcare utilisation of the Dutch type 2 diabetes population is distributed across the health system and utilisation of medical specialist care is high. This is likely to be due to presence of concurrent morbidities and complications. Therefore, a shift from a disease-specific approach to a person-centred and integrated care approach could be beneficial in the treatment of type 2 diabetes.

Citing Articles

Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.

Ahn S Diagnostics (Basel). 2024; 14(14).

PMID: 39061705 PMC: 11276298. DOI: 10.3390/diagnostics14141568.

Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus.

Owen R, Carr H, Counter C, Tingle S, Thompson E, Manas D Transpl Int. 2024; 36:11792.

PMID: 38370534 PMC: 10869449. DOI: 10.3389/ti.2023.11792.

Disentangling Population Health Management Initiatives in Diabetes Care: A Scoping Review.

Geurten R, Struijs J, Bilo H, Ruwaard D, Elissen A Int J Integr Care. 2024; 24(1):3.

PMID: 38312481 PMC: 10836183. DOI: 10.5334/ijic.7512.

Evaluation of Healthcare Utilisation and Expenditures in Persons with Type 2 Diabetes Undergoing Bariatric-Metabolic Surgery.

Monpellier V, Geurten R, Janssen I, Ruwaard D, Struijs J, van Dijk P Obes Surg. 2024; 34(3):723-732.

PMID: 38198097 PMC: 10899363. DOI: 10.1007/s11695-023-06849-z.

References

van Schoonhoven A, Gout-Zwart J, de Vries M, van Asselt A, Dvortsin E, Vemer P . Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review. PLoS One. 2019; 14(9):e0221856. PMC: 6730996. DOI: 10.1371/journal.pone.0221856. View

Nathanson D, Sabale U, Eriksson J, Nystrom T, Norhammar A, Olsson U . Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014. Pharmacoecon Open. 2018; 2(4):393-402. PMC: 6249189. DOI: 10.1007/s41669-017-0063-y. View

Slabaugh S, Curtis B, Clore G, Fu H, Schuster D . Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US. J Med Econ. 2014; 18(2):106-12. DOI: 10.3111/13696998.2014.979292. View

Zgibor J, Orchard T, Saul M, Piatt G, Ruppert K, Stewart A . Developing and validating a diabetes database in a large health system. Diabetes Res Clin Pract. 2006; 75(3):313-9. DOI: 10.1016/j.diabres.2006.07.007. View

Berntsen G, Hoyem A, Lettrem I, Ruland C, Rumpsfeld M, Gammon D . A person-centered integrated care quality framework, based on a qualitative study of patients' evaluation of care in light of chronic care ideals. BMC Health Serv Res. 2018; 18(1):479. PMC: 6011266. DOI: 10.1186/s12913-018-3246-z. View

Muller N, Heller T, Freitag M, Gerste B, Haupt C, Wolf G . Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med. 2015; 32(7):951-7. DOI: 10.1111/dme.12747. View

Hrzic R, Clemens T, Westra D, Brand H . Comparability in Cross-National Health Research Using Insurance Claims Data: The Cases of Germany and The Netherlands. Gesundheitswesen. 2019; 82(S 01):S83-S90. DOI: 10.1055/a-1005-6792. View

Hazel-Fernandez L, Li Y, Nero D, Moretz C, Slabaugh L, Meah Y . Relationship of diabetes complications severity to healthcare utilization and costs among Medicare Advantage beneficiaries. Am J Manag Care. 2015; 21(1):e62-70. View

Nichols G, Desai J, Lafata J, Lawrence J, OConnor P, Pathak R . Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis. 2012; 9:E110. PMC: 3457753. DOI: 10.5888/pcd9.110311. View

10.

Alzaid A, Ladron de Guevara P, Beillat M, Lehner Martin V, Atanasov P . Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Rev Pharmacoecon Outcomes Res. 2020; 21(4):785-798. DOI: 10.1080/14737167.2020.1782748. View

11.

Struijs J, Baan C, Schellevis F, Westert G, van den Bos G . Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res. 2006; 6:84. PMC: 1534031. DOI: 10.1186/1472-6963-6-84. View

12.

de Groot S, Enters-Weijnen C, Geelhoed-Duijvestijn P, Kanters T . A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open. 2018; 8(3):e019864. PMC: 5875590. DOI: 10.1136/bmjopen-2017-019864. View

13.

Williams R, Van Gaal L, Lucioni C . Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002; 45(7):S13-7. DOI: 10.1007/s00125-002-0859-9. View

14.

Pagano E, de Rosa M, Rossi E, Cinconze E, Marchesini G, Miccoli R . The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis. 2016; 26(10):944-50. DOI: 10.1016/j.numecd.2016.05.002. View

15.

Jacobs E, Hoyer A, Brinks R, Icks A, Kuss O, Rathmann W . Healthcare costs of Type 2 diabetes in Germany. Diabet Med. 2017; 34(6):855-861. DOI: 10.1111/dme.13336. View

16.

Jonsson B . Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002; 45(7):S5-12. DOI: 10.1007/s00125-002-0858-x. View

17.

Li R, Bilik D, Brown M, Zhang P, Ettner S, Ackermann R . Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013; 19(5):421-30. PMC: 4337403. View

18.

Janssen L, Hiligsmann M, Elissen A, Joore M, Schaper N, Bosma J . Burden of disease of type 2 diabetes mellitus: cost of illness and quality of life estimated using the Maastricht Study. Diabet Med. 2020; 37(10):1759-1765. PMC: 7539911. DOI: 10.1111/dme.14285. View

19.

Mitri J, Gabbay R . Understanding Population Health Through Diabetes Population Management. Endocrinol Metab Clin North Am. 2016; 45(4):933-942. DOI: 10.1016/j.ecl.2016.06.006. View

20.

Dworsky M . Using All-Payer Claims Databases to Study Insurance and Health Care Utilization Dynamics. J Gen Intern Med. 2017; 32(10):1069-1070. PMC: 5602770. DOI: 10.1007/s11606-017-4128-5. View